Why performance status? A case for alternative functional assessments in pediatric oncology clinical trials
- PMID: 34196972
- DOI: 10.1002/cncr.33741
Why performance status? A case for alternative functional assessments in pediatric oncology clinical trials
Keywords: PROs; clinical trials; patient-reported outcomes; pediatrics; performance status.
Comment on
-
Patients, caregivers, and clinicians differ in performance status ratings: Implications for pediatric cancer clinical trials.Cancer. 2021 Oct 1;127(19):3664-3670. doi: 10.1002/cncr.33740. Epub 2021 Jul 1. Cancer. 2021. PMID: 34196962 Free PMC article.
References
-
- Carceller F, Bautista FJ, Jimenez I, et al. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: an Innovative Therapies for Children With Cancer study. Eur J Cancer. 2016;67:130-140.
-
- Chow R, Bruera E, Temel JS, Krishnan M, Im J, Lock M. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. Support Care Cancer. 2020;28:2071-2078.
-
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
-
- Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987;60:1651-1656.
-
- Maurer SH, Hinds PS, Reeve BB, et al. Patients, caregivers, and clinicians differ in performance status ratings: implications for pediatric cancer clinical trials. Cancer. 2021;127:3664-3670.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
